^
    Apply
    Phase I of Histone Deacetylase (HDAC) Inhibitor Panobinostat With Ipilimumab With Unresectable III/IV Melanoma (NCT02032810)
    Phase 1
    H. Lee Moffitt Cancer Center and Research Insti...
    Completed
    Last update posted :
    01/20/2023
    Initiation :
    01/07/2014
    Primary completion :
    09/06/2017
    Completion :
    09/25/2019
    IL2
    |
    Yervoy (ipilimumab) • Farydak (panobinostat)
    Panobinostat Biological Correlates Study (NCT01658241)
    Phase 2
    Peter MacCallum Cancer Centre, Australia
    Completed
    Last update posted :
    05/06/2022
    Initiation :
    07/16/2012
    Primary completion :
    03/18/2015
    Completion :
    03/18/2015
    TNFRSF8
    |
    Farydak (panobinostat)
    Non-Invasive Focused Ultrasound (FUS) With Oral Panobinostat in Children With Progressive Diffuse Midline Glioma (DMG) (NCT04804709)
    Phase 1
    Cheng-Chia (Fred) Wu
    Active, not recruiting
    Last update posted :
    02/14/2022
    Initiation :
    07/28/2021
    Primary completion :
    12/01/2023
    Completion :
    12/01/2025
    FUS
    |
    Farydak (panobinostat)
    A Trial l of Panobinostat Given in Combination With Trastuzumab and Paclitaxel in Adult Female Patients With HER2 Positive Metastatic Breast Cancer (NCT00788931)
    Phase 1
    Novartis Pharmaceuticals
    Completed
    Last update posted :
    12/19/2020
    Initiation :
    12/01/2008
    Primary completion :
    08/01/2010
    HER-2
    |
    Herceptin (trastuzumab) • paclitaxel • Farydak (panobinostat)
    Trial of LBH589 in Metastatic Thyroid Cancer (NCT01013597)
    Phase 2
    University of Wisconsin, Madison
    Completed
    Last update posted :
    11/29/2019
    Initiation :
    01/01/2010
    Primary completion :
    08/01/2013
    Completion :
    02/01/2016
    NOTCH1
    |
    NOTCH1 expression
    |
    Farydak (panobinostat)
    PDR001 + Panobinostat for Melanoma and NSCLC (NCT03982134)
    Phase 1
    Muhammad Furqan
    Withdrawn
    Last update posted :
    10/04/2019
    Initiation :
    09/01/2019
    Primary completion :
    05/01/2021
    Completion :
    05/01/2022
    EGFR • BRAF • ALK • ROS1 • NTRK3 • NTRK
    |
    BRAF mutation • BRAF V600 • EGFR L858R • EGFR exon 19 deletion • ALK rearrangement • ROS1 fusion
    |
    spartalizumab (PDR001) • Farydak (panobinostat)
    Panobinostat and Letrozole in Treating Patients With Metastatic Breast Cancer (NCT01105312)
    Phase 1/2
    Alliance for Clinical Trials in Oncology
    Completed
    Last update posted :
    06/27/2017
    Initiation :
    09/01/2010
    Primary completion :
    08/01/2013
    Completion :
    09/03/2013
    HER-2 • ER • PGR
    |
    HER-2 negative • PGR positive • PGR negative
    |
    letrozole • Farydak (panobinostat)
    Panobinostat (LBH589) in Patients With Metastatic Melanoma (NCT01065467)
    Phase 1
    Dana-Farber Cancer Institute
    Completed
    Last update posted :
    03/28/2017
    Initiation :
    02/01/2010
    Primary completion :
    03/01/2013
    Completion :
    03/13/2017
    MITF
    |
    Farydak (panobinostat)
    Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors (NCT00878904)
    Phase 1
    University of California, San Francisco
    Completed
    Last update posted :
    03/24/2017
    Initiation :
    09/13/2009
    Primary completion :
    05/01/2013
    Completion :
    10/10/2016
    MUC16
    |
    MUC16 elevation
    |
    epirubicin • Farydak (panobinostat)
    ERB-B4 After Treatment With HDAC Inhibitor in ER+ Tamoxifen Refractory Breast Cancer (NCT00993642)
    Phase 1
    Tulane University Health Sciences Center
    Withdrawn
    Last update posted :
    03/13/2017
    Initiation :
    09/01/2009
    Primary completion :
    09/01/2010
    Completion :
    12/01/2010
    ERBB4
    |
    tamoxifen • Farydak (panobinostat)
    Study of Panobinostat Monotherapy in Women With HER2-negative Locally Recurrent or Metastatic Breast Cancer (NCT00777049)
    Phase 2
    Translational Research in Oncology
    Completed
    Last update posted :
    07/15/2016
    Initiation :
    02/01/2009
    Primary completion :
    04/01/2015
    Completion :
    04/01/2015
    HER-2
    |
    HER-2 negative
    |
    Farydak (panobinostat)
    LBH589 in Combination With Capecitabine Plus/Minus (±) Lapatinib in Breast Cancer Patients (NCT00632489)
    Phase 1
    SCRI Development Innovations, LLC
    Completed
    Last update posted :
    06/08/2015
    Initiation :
    05/01/2008
    Primary completion :
    01/01/2009
    Completion :
    07/01/2011
    HER-2
    |
    lapatinib • capecitabine • Farydak (panobinostat)